DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2013/0224110 A1 Bynoe (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2013/0224110 A1 Bynoe (43) Pub US 201302241 10A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0224110 A1 Bynoe (43) Pub. Date: Aug. 29, 2013 (54) USE OF ADENOSINE RECEPTOR Publication Classification SIGNALING TO MODULATE PERMEABILITY OF BLOOD-BRAIN (51) Int. Cl. BARRIER A 6LX3 L/7076 (2006.01) A 6LX3/59 (2006.01) A6II 45/06 (2006.01) (75) Inventor: Margaret S. Bynoe, Ithaca, NY (US) A613 L/437 (2006.01) (52) U.S. Cl. CPC ........... A6 IK3I/7076 (2013.01); A61 K3I/437 (73) Assignee: CORNELL UNIVERSITY, Ithaca, NY (2013.01); A61 K3I/519 (2013.01); A61 K (US) 45/06 (2013.01) USPC ............ 424/1.49; 514/303: 514/45: 514/267; (21) Appl. No.: 13/823,266 424/649; 424/94.5; 424/133.1: 514/17.7: 514/8.6; 424/85.4; 424/143.1; 424/141.1; (22) PCT Fled: Sep. 16, 2011 424/147.1:435/375 (86) PCT NO.: PCT/US 11/51935 (57) ABSTRACT The present invention relates to a method of increasing blood S371 (c)(1), brain barrier (“BBB) permeability in a subject. This method (2), (4) Date: May 14, 2013 involves administering to the Subject an agentoragents which activate both of the A1 and A2A adenosine receptors. Also disclosed is a method to decrease BBB permeability in a Related U.S. Application Data Subject. This method includes administering to the Subject an agent which inhibits or blocks the A2A adenosine receptor (60) Provisional application No. 61/383,628, filed on Sep. signaling. Compositions relating to the same are also dis 16, 2010. closed. Patent Application Publication Aug. 29, 2013 Sheet 1 of 27 US 2013/02241.1.0 A1 xWWWWWWWWWW sw. sy s s: FIG. I. Patent Application Publication Aug. 29, 2013 Sheet 2 of 27 US 2013/02241.1.0 A1 3 * r r s (a r a e R 883.SS R8& (TZ-ÞÝZ'SAOIH s O Patent Application Publication Aug. 29, 2013 Sheet 3 of 27 US 2013/02241.1.0 A1 A. of 3 &E, 83 88 Srs Sinai Casses f of Y3 Otis FIGS 3A-3L Patent Application Publication Aug. 29, 2013 Sheet 4 of 27 US 2013/02241.1.0 A1 FIGS 4A-4K Patent Application Publication Aug. 29, 2013 Sheet 5 of 27 US 2013/02241.1.0 A1 8 3. s & cd73 S s C Rays Fest Nix3 inruixatics WI & ca73 s $$. s says Post NKXs irrizatios FIGS 5A-5C Patent Application Publication Aug. 29, 2013 Sheet 6 of 27 US 2013/02241.1.0 A1 (19 V9'SAOIH Patent Application Publication Aug. 29, 2013 Sheet 7 of 27 US 2013/02241.1.0 A1 (TZ-ÞÝZ"S01.H. ºw,w ?S?HAA!. & s g s s S S S & s 3Es St s e Six lite tiosseids. YN is stee Jia's sistiegy & R K s 's- O eleasy tea Patent Application Publication Aug. 29, 2013 Sheet 8 of 27 US 2013/02241.1.0 A1 Patent Application Publication Aug. 29, 2013 Sheet 9 of 27 US 2013/02241.1.0 A1 aaaaaaaaa. SI 3-iss NSA socio w Pss S. W. SCS828 Cotic ft) dye G. A Patent Application Publication Aug. 29, 2013 Sheet 10 of 27 US 2013/02241.1.0 A1 s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s *************************************************** E. Ey. sy iii.33. SAE sists $53ss &isiteis gigs Patent Application Publication Aug. 29, 2013 Sheet 11 of 27 US 2013/02241.1.0 A1 MEC3Seeted raisweis Xxxxxxxxxxxxxxxxxxxx Patent Application Publication Aug. 29, 2013 Sheet 12 of 27 US 2013/02241.1.0 A1 Ešiši; -is: ess sssssss $$Sašes 8 S. SE systost 8&iressexistix F. Patent Application Publication Aug. 29, 2013 Sheet 14 of 27 US 2013/02241.1.0 A1 91ora S. & it' it 8.338& is is s Patent Application Publication Aug. 29, 2013 Sheet 15 of 27 US 2013/02241.1.0 A1 s s s s s'. i. a 83 St: A Stiei Patent Application Publication Aug. 29, 2013 Sheet 16 of 27 US 2013/02241.1.0 A1 x - | Wt OWt given PEG-ADA s 3. - Y i . s s says Post ROG initiation FIG. 18 Patent Application Publication Aug. 29, 2013 Sheet 17 of 27 US 2013/02241.1.0 A1 s: - k 2: is agg es: .2: .4: :Eag. MECA (ing/kg) FIG. I.94 - : y 3. 2 & C3 S 3. NECA g/kg) FIG. I.9B Patent Application Publication Aug. 29, 2013 Sheet 18 of 27 US 2013/02241.1.0 A1 8 8. $4 - 2 S.S. S. 2: tire after wehicle: NECA injection h; -oirs after vehicle/NECA injection FIG. 20A t s igtss afterweisei-ECA injection FIG. 20B Patent Application Publication Aug. 29, 2013 Sheet 19 of 27 US 2013/02241.1.0 A1 3. s 3. 2 - - - - - - C3 FIG. 2 IA Brain AR Expression on Brain AR Expression of Endothetial Celis (IF) Erdothetia Ceis (FISH) 3. FIG 21B FIG. 21C Primary Brain Endotheia Ces AAR AAR FIG. 2 ID Patent Application Publication Aug. 29, 2013 Sheet 20 of 27 US 2013/02241.1.0 A1 - G.25 a 9.35 s ON E S S. G.3 Yr 2 - . S S 8.25 C S - C - s w se - .35 . a - rw F - 5 - t { 0.8 - k- - .' -- , As FIG 21E FIG. 2 IF e 3.25 . 8wehicle 5, 0.20 NECA 3.5 5 g O. - 0.05 : goo x WT A' AA- A s SC-5828: FIG 21G Patent Application Publication Aug. 29, 2013 Sheet 21 of 27 US 2013/02241.1.0 A1 0.4 S s is .3 * i. 3 S 5 (.2 c. s --- Q.: - a 0 out s s: - 3x &, a 8x <is fei:cis 3.45 : 54S. S. 4, 4 S 45 EA S.S. c. : GS 2. 3.8:3 CGS 21880 mg/kg FIG. 2 IIH 3. 34 - ..3. 8 E33 . 3. 8.2 : 3. 3. eigs 3: 38, 8.33 3.8 33 Ea &FA isg ( : FIG. 2 II s . S. 2. 3. 5 s S. siege E.A. &S Ra, 8 sis RS W S - C3 & & CCSScerA + FIG. 21. Patent Application Publication Aug. 29, 2013 Sheet 22 of 27 US 2013/02241.1.0 A1 r — 2.0 - E.8 s: a. s s E & 5. 3. 4. is a 1. s - 8 : . os r -s .5 S. C. s “ 0.0 & S 3 as3.2 S v SSS SSS S$ 3 coor Wasgia . S.C. 3x x exiscar (mgikg) FIG. 22A c 25 - 2S 20 s g 20 s s -- has s a s a g Q V G2. G & S. x - C, s S y ickirgki) is--- less s&Ss C. : S 5. 1. :ECA:gkg exsica, gkg ingikg; FIG. 22B Patent Application Publication Aug. 29, 2013 Sheet 23 of 27 US 2013/02241.1.0 A1 a s E g s 3. g 8 as a. s vehicle 1.org Lexiscani,w, FIG. 22C injection 5 min 33 s s 5 s: ).2 frt E 0.4 t e is 0.3 s C. is *- 0.1 i 0.0 O SO 100 w 150 2}} SC) O Si 23 Time after injection min} Time after injectioi (min) . 8.05 - 0.04 3 - 0.02 , - . encies;Se: S: 82 FIG. 22F Patent Application Publication Aug. 29, 2013 Sheet 24 of 27 US 2013/02241.1.0 A1 APP Motse Brains NECA Vehicle Anti-f-amyloid antibody (given i.v. Post-porten anti-3-amyloid staining L. Fros. 234-23 s i s s FIG. 23E Patent Application Publication Aug. 29, 2013 Sheet 25 of 27 US 2013/02241.1.0 A1 CD31 and B-amyloid Stained Art Mouse Brains FIGS. 23F-23G & - S. 3 is S. 20 is sk. t 5. NECA vehicle FIG. 23H Patent Application Publication Aug. 29, 2013 Sheet 26 of 27 US 2013/0224110 A1 A 8enc, 3 Ce:s 3CO S. 3200a & 2 GOs a 8 sasaas rassaaaaaaaaaa-assassarasaasaasaaraasa. i 38 SE 38 3 8 - As www.www.A A. As ClF3 isc, post-treatienti. - x - c.min} - - Eer,3 Cei. Atti. Uptake Šedia Ya3la NECA textsca: e3 Weis & E.8 sys&38. F-acti Staining 3 it 3 nir 8&ia -: stics C88sis EA Cicci ièxiscat FIGS 24A-24Y Patent Application Publication Aug. 29, 2013 Sheet 27 of 27 US 2013/02241.1.0 A1 i A or A2A i. Basal Conditions agonism Š. S S & S. S S Š ar. CNS S & S S Tight BBB Increased BBB permeability iii. A and A2A agon Sm S S. ces S oieces &S Adhesion diecies 7.9 FOd in Creased BBB permeability v. Aga antagonism S $. S FIG. 25 Š recreased BBB permeability US 2013/02241 10 A1 Aug. 29, 2013 USE OF ADENOSINE RECEPTOR cells are also different in that they have few pinocytic vesicles SIGNALING TO MODULATE which in other tissues allow somewhat unselective transport PERMEABILITY OF BLOOD-BRAIN across the capillary wall. Also lacking are continuous gaps or BARRIER channels running between the cells which would allow unre 0001. This application claims the benefit of U.S. Provi stricted passage. sional Patent Application Ser. No. 61/383,628, filed Sep. 16, 0006. The blood-brain barrier functions to ensure that the 2010, which is hereby incorporated by reference in its environment of the brain is constantly controlled.
Load more

Recommended publications
  • Protective Effects of Anthocyanins on the Ectonucleotidase Activity in the Impairment of Memory Induced by Scopolamine in Adult Rats
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Life Sciences 91 (2012) 1221–1228 Contents lists available at SciVerse ScienceDirect Life Sciences journal homepage: www.elsevier.com/locate/lifescie Protective effects of anthocyanins on the ectonucleotidase activity in the impairment of memory induced by scopolamine in adult rats Jessié M. Gutierres a,⁎, Fabiano B. Carvalho a, Maria R.C. Schetinger a, Marília V. Rodrigues a, Roberta Schmatz a, Victor C. Pimentel a, Juliano M. Vieira a, Michele M. Rosa a, Patrícia Marisco a, Daniela A. Ribeiro a, Claudio Leal a, Maribel A. Rubin a, Cinthia M. Mazzanti c, Roselia Spanevello b,⁎⁎ a Departamento de Química, Universidade Federal de Santa Maria, Santa Maria, RS 97105-900, Brazil b Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas, Campus Universitário-Capão do Leão 96010-900 Pelotas, RS, Brazil c Clínica de Pequenos animais, Centro de Ciências Rurais, Universidade Federal de Santa Maria, Santa Maria, RS 97105-900, Brazil article info abstract Article history: Aims: We investigated whether the treatment with anthocyanins prevents the scopolamine-induced memory Received 24 March 2012 deficits and whether ectonucleotidase activities and purine levels are altered in the cerebral cortex (CC) and Accepted 19 September 2012 hippocampus (HC) in this model of mnemonic deficit in rats. Main methods: The animals were divided into 4 experimental groups: control (vehicle), anthocyanins (Antho), Keywords: scopolamine (SCO), and scopolamine plus anthocyanins (SCO+Antho). After seven days of treatment, they Anthocyanins were tested in the inhibitory avoidance task and open field test and submitted to euthanasia.
    [Show full text]
  • Optumrx Brand Pipeline Forecast
    RxOutlook® 1st Quarter 2019 OptumRx brand pipeline forecast Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug 2019 Possible launch date Ophthalmological DS-300 DS-300 Eton undisclosed SC Filed NDA 2019 unknown N disease anti-sclerostin Evenity romosozumab Amgen Osteoporosis SC Filed NDA 2/2019 Y N monoclonal antibody tetrahydrofolate iclaprim iclaprim Motif Bio Bacterial infections IV Filed NDA 2/13/2019 Y Y dehydrogenase inhibitor tazarotene/ IDP-118 Valeant retinoid/ corticosteroid Psoriasis TOP Filed NDA 2/15/2019 N N halobetasol adenosine deaminase Mavenclad cladribine Merck/ Teva resistant Multiple sclerosis PO Filed NDA 2/15/2019 Y N deoxyadenosine analog Lotemax Gel loteprednol Valeant corticosteroid Ocular inflammation OP Filed NDA 2/25/2019 N N Nex Gen etabonate turoctocog alfa glyco-PEGylated factor NN-7088 Novo Nordisk Hemophilia IV/SC Filed BLA 2/27/2019 Y N pegol VIII derivative selective sphingosine-1 BAF-312 siponimod Novartis phosphate receptor Multiple sclerosis PO Filed NDA 3/1/2019 Y N agonist midazolam midazolam UCB benzodiazepine Seizures Intranasal Filed NDA 3/1/2019 N Y (USL-261) XeriSol glucagon Xeris glucagon analog Diabetes mellitus SC Filed NDA 3/1/2019 N N Glucagon optum.com/optumrx 1 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug dopamine receptor JZP-507 sodium oxybate Jazz Narcolepsy
    [Show full text]
  • Safety and Tolerability of Arimoclomol in Patients with Sporadic Inclusion Body Myositis: a Randomised, Double-Blind, Placebo-Controlled, Proof-Of-Concept Trial
    Safety and tolerability of arimoclomol in patients with sporadic inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept trial Sporadic inclusion body myositis (IBM) is the commonest idiopathic inflammatory myopathy (IIM) occurring in patients over the age of 50 years.1-4 The prevalence of IBM differs between different populations and ethnic groups, with estimates between 4.9-70.6 per million population.5-10 IBM is distinguished from the other IIM by early asymmetric finger flexor and knee extensor weakness (leading to loss of hand function and propensity to fall) and resistance to immunosuppressive therapy. Any skeletal muscle can be affected, including oesophageal and pharyngeal muscles. Late-stage disease can be characterized by very significant morbidity including disability and loss of quality of life. Death in IBM is related to malnutrition, cachexia, aspiration, respiratory infection and respiratory failure, as a consequence of dysphagia, severe global weakness and weakness of the respiratory muscles.1-4 In a Dutch cohort, end-of-life care interventions were used by 13% of patients with IBM, highlighting the morbidity experienced by these patients and the need of supportive and palliative care in this disease.2 The aetiopathogenesis of IBM remains uncertain. The varied pathological findings observed have driven a number of theories including viral infection, accumulation of toxic proteins, autoimmune attack, myonuclear degeneration, endoplasmic reticulum stress and impairment of autophagy and proteasomal proteolysis.11-15 Muscle biopsies from patients with IBM typically show several different pathological features broadly described as inflammatory or degenerative. Inflammatory features include endomysial infiltration by mononuclear cells (predominantly CD8+ T- cells), which surround and invade otherwise normal appearing muscle fibres, and overexpression of major histocompatibility complex (MHC) class I, which is not constitutively expressed by skeletal muscle.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Pioneering New Markets Changing the Standard of Care
    ANNUAL 2020 REPORT Pioneering New Markets Changing the Standard of Care UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 33-0336973 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) 2855 Gazelle Court, Carlsbad, CA 92010 (Address of Principal Executive Offices) (Zip Code) 760-931-9200 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol Name of each exchange on which registered Common Stock, $.001 Par Value ‘‘IONS’’ The Nasdaq Stock Market LLC Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No □ Indicate by check if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes □ No ☒ Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Horizon Scanning Status Report June 2019
    Statement of Funding and Purpose This report incorporates data collected during implementation of the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System, operated by ECRI Institute under contract to PCORI, Washington, DC (Contract No. MSA-HORIZSCAN-ECRI-ENG- 2018.7.12). The findings and conclusions in this document are those of the authors, who are responsible for its content. No statement in this report should be construed as an official position of PCORI. An intervention that potentially meets inclusion criteria might not appear in this report simply because the horizon scanning system has not yet detected it or it does not yet meet inclusion criteria outlined in the PCORI Health Care Horizon Scanning System: Horizon Scanning Protocol and Operations Manual. Inclusion or absence of interventions in the horizon scanning reports will change over time as new information is collected; therefore, inclusion or absence should not be construed as either an endorsement or rejection of specific interventions. A representative from PCORI served as a contracting officer’s technical representative and provided input during the implementation of the horizon scanning system. PCORI does not directly participate in horizon scanning or assessing leads or topics and did not provide opinions regarding potential impact of interventions. Financial Disclosure Statement None of the individuals compiling this information have any affiliations or financial involvement that conflicts with the material presented in this report. Public Domain Notice This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated. All statements, findings, and conclusions in this publication are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI) or its Board of Governors.
    [Show full text]
  • Ectonucleotidase Expression on Human Amnion Epithelial Cells
    Ectonucleotidase Expression on Human Amnion Epithelial Cells: Adenosinergic Pathways and Dichotomic Effects on Immune Effector Cell Populations This information is current as of September 28, 2021. Fabio Morandi, Alberto L. Horenstein, Valeria Quarona, Angelo Corso Faini, Barbara Castella, Raghuraman C. Srinivasan, Stephen C. Strom, Fabio Malavasi and Roberto Gramignoli J Immunol published online 26 December 2018 Downloaded from http://www.jimmunol.org/content/early/2018/12/23/jimmun ol.1800432 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2018/12/23/jimmunol.180043 Material 2.DCSupplemental Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 28, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2018 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published December 26, 2018, doi:10.4049/jimmunol.1800432 The Journal of Immunology Ectonucleotidase Expression on Human Amnion Epithelial Cells: Adenosinergic Pathways and Dichotomic Effects on Immune Effector Cell Populations Fabio Morandi,*,1 Alberto L. Horenstein,†,‡,x,1 Valeria Quarona,† Angelo Corso Faini,† Barbara Castella,† Raghuraman C.
    [Show full text]
  • Characterization of the Contractile P2Y14 Receptor in Mouse Coronary and Cerebral Arteries ⇑ Kristian Agmund Haanes , Lars Edvinsson
    FEBS Letters 588 (2014) 2936–2943 journal homepage: www.FEBSLetters.org Characterization of the contractile P2Y14 receptor in mouse coronary and cerebral arteries ⇑ Kristian Agmund Haanes , Lars Edvinsson Department of Clinical Experimental Research, Glostrup Research Institute, Copenhagen University Hospital, Nordre Ringvej 59, 2600 Glostrup, Denmark article info abstract Article history: Extracellular UDP-glucose can activate the purinergic P2Y14 receptor. The aim of the present study Received 13 February 2014 was to examine the physiological importance of P2Y14 receptors in the vasculature. The data pre- Revised 13 May 2014 sented herein show that UDP-glucose causes contraction in mouse coronary and basilar arteries. Accepted 21 May 2014 The EC values and immunohistochemistry illustrated the strongest P2Y14 receptor expression in Available online 6 June 2014 50 the basilar artery. In the presence of pertussis toxin, UDP-glucose inhibited contraction in coronary Edited by Ned Mantei arteries and in the basilar artery it surprisingly caused relaxation. After organ culture of the coro- nary artery, the EC50 value decreased and an increased staining for the P2Y14 receptor was observed, showing receptor plasticity. Keywords: Purinergic receptors Ó 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. P2Y14 Coronary artery Basilar artery Receptor upregulation P2Y2 KO 1. Introduction vasoconstriction in porcine pancreatic arteries [12]. This study was designed to examine the physiological importance
    [Show full text]
  • Advances in Non-Dopaminergic Treatments for Parkinson's Disease
    REVIEW ARTICLE published: 22 May 2014 doi: 10.3389/fnins.2014.00113 Advances in non-dopaminergic treatments for Parkinson’s disease Sandy Stayte 1,2 and Bryce Vissel 1,2* 1 Neuroscience Department, Neurodegenerative Disorders Laboratory, Garvan Institute of Medical Research, Sydney, NSW, Australia 2 Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia Edited by: Since the 1960’s treatments for Parkinson’s disease (PD) have traditionally been directed Eero Vasar, University of Tartu, to restore or replace dopamine, with L-Dopa being the gold standard. However, chronic Estonia L-Dopa use is associated with debilitating dyskinesias, limiting its effectiveness. This has Reviewed by: resulted in extensive efforts to develop new therapies that work in ways other than Andrew Harkin, Trinity College Dublin, Ireland restoring or replacing dopamine. Here we describe newly emerging non-dopaminergic Sulev Kõks, University of Tartu, therapeutic strategies for PD, including drugs targeting adenosine, glutamate, adrenergic, Estonia and serotonin receptors, as well as GLP-1 agonists, calcium channel blockers, iron Pille Taba, Universoty of Tartu, chelators, anti-inflammatories, neurotrophic factors, and gene therapies. We provide a Estonia Pekka T. Männistö, University of detailed account of their success in animal models and their translation to human clinical Helsinki, Finland trials. We then consider how advances in understanding the mechanisms of PD, genetics, *Correspondence: the possibility that PD may consist of multiple disease states, understanding of the Bryce Vissel, Neuroscience etiology of PD in non-dopaminergic regions as well as advances in clinical trial design Department, Neurodegenerative will be essential for ongoing advances. We conclude that despite the challenges ahead, Disorders Laboratory, Garvan Institute of Medical Research, patients have much cause for optimism that novel therapeutics that offer better disease 384 Victoria Street, Darlinghurst, management and/or which slow disease progression are inevitable.
    [Show full text]
  • Health Plan Insights
    Health Plan Insights January 2020 Updates from December 2019 800.361.4542 | envisionrx.com Confidential - Document has confidential information and may not be copied, published or distributed, in whole or in part, in any form or medium, without EnvisionRxOptions’ prior written consent. Recent FDA Approvals New Medications TRADE NAME DOSAGE FORM APPROVAL MANUFACTURER INDICATION(S) (generic name) STRENGTH DATE Avsola Amgen Inc. Injection, Biosimilar to Remicade. For the treatment December 6, 2019 (infliximab-axxq) 100 mg/20 mL of/reducing the signs and symptoms of: Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, rheumatoid arthritis in combination with methotrexate, psoriatic arthritis, and plaque psoriasis. Vyondys 53 Sarepta Intravenous Solution, For the treatment of Duchenne muscular December 12, (golodirsen) Therapeutics, Inc. 50 mg/mL dystrophy (DMD) in patients who have a 2019 confirmed mutation of the DMD gene that is amenable to exon 53 skipping. Padcev Astellas Injection, For the treatment of adult patients with locally December 18, (enfortumab 20 mg/vial and 30 advanced or metastatic urothelial cancer who 2019 vedotin-ejfv) mg/vial have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. Conjupri CSPC Ouyi Tablets, For use alone or in combination with other (levamlodipine) Pharmaceutical 1.25 mg, 2.5 mg, and antihypertensive agents for the treatment of December 19, Co., Ltd. 5 mg hypertension, to lower blood pressure. 2019 Caplyta Intra-Cellular Capsules, For the treatment of schizophrenia in adults. December 20, (lumateperone) Therapies, Inc.
    [Show full text]
  • The Interaction of Selective A1 and A2A Adenosine Receptor Antagonists with Magnesium and Zinc Ions in Mice: Behavioural, Biochemical and Molecular Studies
    International Journal of Molecular Sciences Article The Interaction of Selective A1 and A2A Adenosine Receptor Antagonists with Magnesium and Zinc Ions in Mice: Behavioural, Biochemical and Molecular Studies Aleksandra Szopa 1,* , Karolina Bogatko 1, Mariola Herbet 2 , Anna Serefko 1 , Marta Ostrowska 2 , Sylwia Wo´sko 1, Katarzyna Swi´ ˛ader 3, Bernadeta Szewczyk 4, Aleksandra Wla´z 5, Piotr Skałecki 6, Andrzej Wróbel 7 , Sławomir Mandziuk 8, Aleksandra Pochodyła 3, Anna Kudela 2, Jarosław Dudka 2, Maria Radziwo ´n-Zaleska 9, Piotr Wla´z 10 and Ewa Poleszak 1,* 1 Chair and Department of Applied and Social Pharmacy, Laboratory of Preclinical Testing, Medical University of Lublin, 1 Chod´zkiStreet, PL 20–093 Lublin, Poland; [email protected] (K.B.); [email protected] (A.S.); [email protected] (S.W.) 2 Chair and Department of Toxicology, Medical University of Lublin, 8 Chod´zkiStreet, PL 20–093 Lublin, Poland; [email protected] (M.H.); [email protected] (M.O.); [email protected] (A.K.) [email protected] (J.D.) 3 Chair and Department of Applied and Social Pharmacy, Medical University of Lublin, 1 Chod´zkiStreet, PL 20–093 Lublin, Poland; [email protected] (K.S.);´ [email protected] (A.P.) 4 Department of Neurobiology, Polish Academy of Sciences, Maj Institute of Pharmacology, 12 Sm˛etnaStreet, PL 31–343 Kraków, Poland; [email protected] 5 Department of Pathophysiology, Medical University of Lublin, 8 Jaczewskiego Street, PL 20–090 Lublin, Poland; [email protected] Citation: Szopa, A.; Bogatko, K.; 6 Department of Commodity Science and Processing of Raw Animal Materials, University of Life Sciences, Herbet, M.; Serefko, A.; Ostrowska, 13 Akademicka Street, PL 20–950 Lublin, Poland; [email protected] M.; Wo´sko,S.; Swi´ ˛ader, K.; Szewczyk, 7 Second Department of Gynecology, 8 Jaczewskiego Street, PL 20–090 Lublin, Poland; B.; Wla´z,A.; Skałecki, P.; et al.
    [Show full text]
  • A Differential Role for the Adenosine A2A Receptor in Opiate Reinforcement Vs Opiate-Seeking Behavior
    Neuropsychopharmacology (2009) 34, 844–856 & 2009 Nature Publishing Group All rights reserved 0893-133X/09 $32.00 www.neuropsychopharmacology.org A Differential Role for the Adenosine A2A Receptor in Opiate Reinforcement vs Opiate-Seeking Behavior 1,2 2 1,3 4 Robyn Mary Brown , Jennifer Lynn Short , Michael Scott Cowen , Catherine Ledent and ,1,3 Andrew John Lawrence* 1Brain Injury and Repair Group, Howard Florey Institute, University of Melbourne, Parkville, VIC, Australia; 2Monash Institute of Pharmaceutical 3 4 Sciences, Parkville, VIC, Australia; Centre for Neuroscience, University of Melbourne, Parkville, VIC, Australia; Faculte de Medecine, Institut de Recherche Interdisciplinaire, Universite de Bruxelles, Brussels, Belgium The adenosine A2A receptor is specifically enriched in the medium spiny neurons that make up the ‘indirect’ output pathway from the ventral striatum, a structure known to have a crucial, integrative role in processes such as reward, motivation, and drug-seeking behavior. In the present study we investigated the impact of adenosine A receptor deletion on behavioral responses to morphine in a number of 2A reward-related paradigms. The acute, rewarding effects of morphine were evaluated using the conditioned place preference paradigm. Operant self-administration of morphine on both fixed and progressive ratio schedules as well as cue-induced drug-seeking was assessed. In addition, the acute locomotor response to morphine as well as sensitization to morphine was evaluated. Decreased morphine self- administration and breakpoint in A2A knockout mice was observed. These data support a decrease in motivation to consume the drug, perhaps reflecting diminished rewarding effects of morphine in A2A knockout mice. In support of this finding, a place preference to morphine was not observed in A knockout mice but was present in wild-type mice.
    [Show full text]